Hormone Replacement Therapy in 2026: Is Menopausal Hormone Therapy (MHT) Safe for Women in Their 40s and 50s?

Hormone replacement therapy (HRT) is getting a much‑needed update, and that’s good news for many women in midlife. The latest research shows that for most healthy women who start HRT within 10 years of their final period or before age 60, the benefits often outweigh the risks.

The window of opportunity for Hormone Replacement Therapy (HRT)

In this “window of opportunity,” HRT can ease vasomotor symptoms (hot flashes and night sweats), improve sleep, improve symptoms associated with vaginal dryness or bladder issues, prevent bone loss and prevent osteoporosis, and may also support heart and metabolic health, without clearly increasing breast cancer risk for many appropriately selected patients.

"Keeping in mind that prevention strategies must be personalized, health-care providers and patients can use cumulated HRT data in making clinical decisions concerning chronic disease prevention including CVD and mortality reduction." (Hodis et al, 2023)

A lot of past fears around HRT came from older studies where women started hormones much later in life, often after age 60, when blood vessel and clotting risks are already higher. Updated research now separate younger, early‑postmenopausal women from older groups and show that, in the right candidates, overall cardiovascular risk does not significantly increase—and may even improve with better blood pressure, cholesterol, and glucose control.

Personalized Care for HRT prescribing

Today, medical guidelines strongly emphasize that HRT decisions should be personalized rather than “all good” or “all bad.” The 2025 European Society of Endocrinology guidelines recommend looking carefully at:

1. your personal and family history
2. your symptoms, other health conditions
3. your goals before starting or avoiding hormones.

The form of Hormone Replacement Therapy matters

The type of hormone and how you take it also matter: using estrogen through the skin "transdermal"(for example, a patch or gel) is linked with a lower risk of blood clots than traditional oral pills, especially in women who already have a higher baseline clotting risk.

The simultaneous use of a progestogen (also known as a progesterone that helps to prevent the thickening of the endometrial lining) for example Prometrium or "oral micronized progesterone" or the use of an Intrauterine Device (IUD) such as the Mirena IUD that secretes levonorgesterol.

"Timing of initiation of HRT has significant biological and clinical consequences for women since clinical consequences of most aging-related diseases manifest in women on average 10 years after menopause." (Hodis, et al, 2023)

HRT developments have coincided with major regulatory changes

 In 2025, the U.S. Food and Drug Administration (FDA) brought together an expert panel to reassess longstanding boxed warnings on vaginal estrogen therapies. From these meetings, the FDA and Department of Health and Human Services (HHS) endorsed changes to these warnings, citing decades of accumulated data that refute outdated risk characterizations from the Women's Health Initiative (WHI) in 2002.

This shift in understanding has helped improve public health communication by supporting more open, evidence-led conversations between doctors and patients about HRT.

In the last two decades research all support the timing and type hypotheses: starting HRT near menopause, in appropriately selected lower‑risk women, and choosing safer regimens (e.g., transdermal estrogen, body‑identical progesterone) yields a more favourable benefit–risk profile.

If you are in your 40's or 50's and struggling with menopausal symptoms, HRT may be one option in a broader toolkit that also includes lifestyle, non‑hormonal treatments, and targeted supplements. The next step is a detailed conversation with a primary care provider focused on menopausal health, who understands midlife women’s health and can help you weigh the real‑world pros and cons for your unique situation.

If you would like to book a discovery call with Dr. Amy please click here.

To your best health,

Dr. Amy J. Tung, ND

Naturopathic Doctor | Menopause Society Certified Practitioner (MSCP)

References

Ahmed, A., & Laurent, R. (2025). Comparative symptom relief in various HRT regimens: A multicenter

study. BMC Women's Health, 25, Article 3929.  

Canonico M, et al. Transdermal Estrogen Therapy in Menopausal Women at Increased Risk for Thrombotic Events: A Scoping Review. Thromb Res. 2022;214:1‑8.

Hodis HN, Mack WJ. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing. Cancer J. 2022 May-Jun 01;28(3):208-223. doi: 10.1097/PPO.0000000000000591. PMID: 35594469; PMCID: PMC9178928.

Henderson, V. W., & Azziz, R. (2025). Long-term effects of 4 years of menopausal hormone therapy on

brain aging: A neuroimaging cohort. Menopause, 32(9), 1015–1023.

Khoudary, S. R., Manson, J. E., Santoro, N., Hodis, H. N., & Miller, V. M. (2025). Menopausal hormone

therapy: 30 years of advances and controversies. Endocrine Practice, 31(2), 120–132.

https://doi.org/10.1016/j.eprac.2025.01.001

Lumsden MA, et al. European Society of Endocrinology Clinical Practice Guideline on the Management of Menopause. Eur J Endocrinol. 2025;193(4):G1‑G45. European Society of Endocrinology. (2025). Clinical practice guideline for the management and evaluation of menopause and perimenopause.

Makary MA. Updated Labeling for Menopausal Hormone Therapy. JAMA. 2025;334(2):123‑125.

​

Martin, L. M., & Zhao, Y. (2025). Effectiveness of estrogen therapy on sleep and sexual function in

postmenopausal women: A meta-analysis. International Journal of Molecular Sciences, 26(22), 11098.

Manson JE, et al. Hormone Therapy for Menopausal Vasomotor Symptoms and Chronic Disease Risk: A Review. JAMA Intern Med. 2025;185(9):e123456.

Mikkola TS, Clarkson TB. Menopausal Hormone Replacement Therapy and Reduction of All‑Cause Mortality and Cardiovascular Disease. Ann Med. 2004;36(5):310‑323.

Smith, K. A., & Reynolds, R. F. (2025). Discontinuation of menopausal hormone therapy and long-term

fracture and cardiovascular risk: A cohort analysis. The Lancet Healthy Longevity, 6(3), 201–213.

https://doi.org/10.1016/S2666-7568(25)00048-0

U.S. Food and Drug Administration. (2025). FDA expert panel on menopause and hormone replacement therapy for women. 

U.S. Department of Health and Human Services. (2025). HHS advances women's health: Removes

misleading boxed warnings from hormone replacement therapy. 

Disclaimer:

The information in this blog is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your doctor or other qualified health professional with any questions regarding a medical condition or treatment. Never disregard professional medical advice or delay seeking treatment because of something you have read in this blog.

Individual results may vary, and the strategies discussed here are not guaranteed to work for everyone. This content does not create a patient-client relationship and should not be used as a replacement for personalized medical care.